Citadel Advisors
MDVX

Citadel Advisors’s Medovex Corp. Common Stock MDVX Stock Holding History

Citadel Advisors’s Portfolio MDVX Stock Details MDVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-29,298
Closed -$26K – 8442
2017
Q2 		$26K Buy
+29,298
New +$34.2K ﹤0.01% 7239
2017
Q1 		– Sell
-15,477
Closed -$21K – 8427
2016
Q4 		$21K Buy
15,477
+2,393
+18% +$3.55K ﹤0.01% 7083
2016
Q3 		$19K Sell
13,084
-1,711
-12% -$2.42K ﹤0.01% 7077
2016
Q2 		$19K Buy
14,795
+2,498
+20% +$3.4K ﹤0.01% 6640
2016
Q1 		$13K Sell
12,297
-2,358
-16% -$2.94K ﹤0.01% 6574
2015
Q4 		$16K Buy
+14,655
New +$22.8K ﹤0.01% 8097

Other funds holding MDVX

MIC
Meridian Investment Counsel Lafayette, California $466M AUM 42.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BW
Bison Wealth Atlanta, Georgia $454M AUM 22.8% 1-Year Est. Return
PP
Patten & Patten Chattanooga, Tennessee $1.66B AUM 18.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Citadel Advisors's MDVX Position: Q3 2017 in Review

Citadel Advisors sold out of Medovex Corp. Common Stock (MDVX) in Q3 2017, closing a stake of 29,298 shares — an estimated $26K sold.

Citadel Advisors first reported a position in MDVX in Q4 2015 and held it in 6 quarters. The position peaked at $26K in Q2 2017. 8 funds tracked by Wall St. Rank hold MDVX as of Q3 2017.

  • Citadel Advisors reported no remaining Medovex Corp. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Citadel Advisors sold 29,298 Medovex Corp. Common Stock shares in Q3 2017, an estimated $26K.
  • Citadel Advisors first reported a position in Medovex Corp. Common Stock in Q4 2015 and held it in 6 quarters.
  • Citadel Advisors's Medovex Corp. Common Stock position peaked at $26K in Q2 2017.
  • 8 funds tracked by Wall St. Rank held Medovex Corp. Common Stock as of Q3 2017.

Based on Citadel Advisors's 13F filing for Q3 2017, filed 9 Nov 2017.